FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246117123> ?p ?o ?g. }

• W4246117123 abstract "Background The anti‐CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far. Objectives To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing remitting multiple sclerosis. Search methods We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group's Trials Register (February 2012), MEDLINE (January 1966 to February 2012), EMBASE (January 1985 to February 2012). At the same time, we handsearched the references quoted in the identified trials reports (February 2012) from the most important neurological associations and MS Societies. Contacts with researchers participating in trials on daclizumab have been established. Selection criteria All randomized controlled clinical trials (RCTs) evaluating daclizumab, alone or combined with other treatments versus placebo, or any other treatment for patients with RRMS. Data collection and analysis Two review authors independently assessed references retrieved for possible inclusion. Disagreements regarding inclusion were resolved by consensus. We contacted study authors for additional information. We collected adverse effects information from the trials. Main results We identified 470 references from all electronic databases searched excluding duplicate. After screening of titles and abstracts, full papers of 10 studies were obtained and assessed for eligibility. An additional ongoing trial was found. Only one trial (230 participants) evaluating the efficacy of daclizumab versus placebo in interferon beta treated patients was included. It was judged as of high quality study. No significant difference was found in the expanded disability score changes and the annualised relapse rate comparing treated versus placebo groups. No significant difference of common adverse events was found across all the groups at the endpoint. The mean number of new or enlarged gadolinium contrast‐enhancing lesions was significantly decreased in the interferon beta and high‐dose daclizumab group, compared with that in the interferon beta and placebo group. Authors' conclusions Daclizumab is well tolerated in combination with interferon beta treated multiple sclerosis population. Comparing with placebo, high‐dose daclizumab can significantly decreased the number of new or enlarged gadolinium contrast‐enhancing lesions. However, the evidence of recommendation is insufficient. More well‐designed RCTs or crossover controlled trials are required to evaluate the efficacy and safety of daclizumab." @default.
• W4246117123 created "2022-05-12" @default.
• W4246117123 creator A5023893251 @default.
• W4246117123 creator A5064279479 @default.
• W4246117123 creator A5070369468 @default.
• W4246117123 creator A5087900366 @default.
• W4246117123 date "2012-04-18" @default.
• W4246117123 modified "2023-10-16" @default.
• W4246117123 title "Daclizumab for relapsing remitting multiple sclerosis" @default.
• W4246117123 cites W1733558371 @default.
• W4246117123 cites W1975104912 @default.
• W4246117123 cites W1975389005 @default.
• W4246117123 cites W1984999645 @default.
• W4246117123 cites W1996481500 @default.
• W4246117123 cites W1996773578 @default.
• W4246117123 cites W2009570912 @default.
• W4246117123 cites W2057237240 @default.
• W4246117123 cites W2075740779 @default.
• W4246117123 cites W2090207085 @default.
• W4246117123 cites W2095636772 @default.
• W4246117123 cites W2101409687 @default.
• W4246117123 cites W2105490558 @default.
• W4246117123 cites W2113485611 @default.
• W4246117123 cites W2113754168 @default.
• W4246117123 cites W2114942536 @default.
• W4246117123 cites W2121931605 @default.
• W4246117123 cites W2130355701 @default.
• W4246117123 cites W2916040650 @default.
• W4246117123 cites W4241890711 @default.
• W4246117123 doi "https://doi.org/10.1002/14651858.cd008127.pub3" @default.
• W4246117123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22513956" @default.
• W4246117123 hasPublicationYear "2012" @default.
• W4246117123 type Work @default.
• W4246117123 citedByCount "6" @default.
• W4246117123 countsByYear W42461171232012 @default.
• W4246117123 countsByYear W42461171232013 @default.
• W4246117123 countsByYear W42461171232014 @default.
• W4246117123 countsByYear W42461171232015 @default.
• W4246117123 crossrefType "reference-entry" @default.
• W4246117123 hasAuthorship W4246117123A5023893251 @default.
• W4246117123 hasAuthorship W4246117123A5064279479 @default.
• W4246117123 hasAuthorship W4246117123A5070369468 @default.
• W4246117123 hasAuthorship W4246117123A5087900366 @default.
• W4246117123 hasConcept C126322002 @default.
• W4246117123 hasConcept C142724271 @default.
• W4246117123 hasConcept C168563851 @default.
• W4246117123 hasConcept C1862650 @default.
• W4246117123 hasConcept C187212893 @default.
• W4246117123 hasConcept C197934379 @default.
• W4246117123 hasConcept C203014093 @default.
• W4246117123 hasConcept C204787440 @default.
• W4246117123 hasConcept C27081682 @default.
• W4246117123 hasConcept C2779719350 @default.
• W4246117123 hasConcept C2780640218 @default.
• W4246117123 hasConcept C2781028063 @default.
• W4246117123 hasConcept C2908698914 @default.
• W4246117123 hasConcept C2909675724 @default.
• W4246117123 hasConcept C2911091166 @default.
• W4246117123 hasConcept C2994247566 @default.
• W4246117123 hasConcept C3020694758 @default.
• W4246117123 hasConcept C44249647 @default.
• W4246117123 hasConcept C535046627 @default.
• W4246117123 hasConcept C71924100 @default.
• W4246117123 hasConceptScore W4246117123C126322002 @default.
• W4246117123 hasConceptScore W4246117123C142724271 @default.
• W4246117123 hasConceptScore W4246117123C168563851 @default.
• W4246117123 hasConceptScore W4246117123C1862650 @default.
• W4246117123 hasConceptScore W4246117123C187212893 @default.
• W4246117123 hasConceptScore W4246117123C197934379 @default.
• W4246117123 hasConceptScore W4246117123C203014093 @default.
• W4246117123 hasConceptScore W4246117123C204787440 @default.
• W4246117123 hasConceptScore W4246117123C27081682 @default.
• W4246117123 hasConceptScore W4246117123C2779719350 @default.
• W4246117123 hasConceptScore W4246117123C2780640218 @default.
• W4246117123 hasConceptScore W4246117123C2781028063 @default.
• W4246117123 hasConceptScore W4246117123C2908698914 @default.
• W4246117123 hasConceptScore W4246117123C2909675724 @default.
• W4246117123 hasConceptScore W4246117123C2911091166 @default.
• W4246117123 hasConceptScore W4246117123C2994247566 @default.
• W4246117123 hasConceptScore W4246117123C3020694758 @default.
• W4246117123 hasConceptScore W4246117123C44249647 @default.
• W4246117123 hasConceptScore W4246117123C535046627 @default.
• W4246117123 hasConceptScore W4246117123C71924100 @default.
• W4246117123 hasLocation W42461171231 @default.
• W4246117123 hasLocation W42461171232 @default.
• W4246117123 hasOpenAccess W4246117123 @default.
• W4246117123 hasPrimaryLocation W42461171231 @default.
• W4246117123 hasRelatedWork W2002450319 @default.
• W4246117123 hasRelatedWork W2020547029 @default.
• W4246117123 hasRelatedWork W2153143281 @default.
• W4246117123 hasRelatedWork W2159343111 @default.
• W4246117123 hasRelatedWork W2316494973 @default.
• W4246117123 hasRelatedWork W2394374926 @default.
• W4246117123 hasRelatedWork W2510526558 @default.
• W4246117123 hasRelatedWork W2596124090 @default.
• W4246117123 hasRelatedWork W2774372363 @default.
• W4246117123 hasRelatedWork W4385646655 @default.
• W4246117123 isParatext "false" @default.
• W4246117123 isRetracted "false" @default.
• W4246117123 workType "reference-entry" @default.